Identification of proteomic biomarkers in maternal plasma in the early second trimester that predict the subsequent development of gestational diabetes

Reproductive Sciences

Volumn 19, Issue 2, 2012, Pages 202-209

  Kim, Sun Min ^a   Park, Joong Shin ^a   Norwitz, Errol R ^b   Lee, Seung Mi ^a   Kim, Byoung Jae ^a   Park, Chan Wook ^a   Jun, Jong Kwan ^a   Kim, Chul Woo ^a   Syn, Hee Chul ^a  

^a Seoul National University   (South Korea)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoprotein AII; apolipoprotein CIII; gestational diabetes; proteomics; SELDI TOF

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN C3;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MATERNAL BLOOD; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEOMICS; SECOND TRIMESTER PREGNANCY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; DIABETES, GESTATIONAL; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PROSPECTIVE STUDIES; PROTEIN ISOFORMS; PROTEOMICS; UP-REGULATION;

EID: 84859886894     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719111417889     Document Type: Article

References (34)

1. Adams KM, Li H, Nelson RL, Ogburn PL Jr, Danilenko-Dixon DR. Sequelae of unrecognized gestational diabetes. Am J Obstet Gynecol. 1998;178(6):1321-1332.
2. Casey BM, Lucas MJ, McIntire DD, Leveno KJ. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol. 1997;90(6):869-873.
3. Xiong X, Saunders LD, Wang FL, Demianczuk NN. Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. Int J Gynaecol Obstet. 2001;75(3):221-228.
4. Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol. 2005; 192(4):989-997.
5. Coustan DR, Carpenter MW, O'Sullivan PS, Carr SR. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol. 1993;168(4):1139-1144.
6. Yogev Y, Xenakis EMJ, Langer O. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. Am J Obstet Gynecol. 2004;191(5):1655-1660.
7. Getahun D, Nath C, Ananth CV, Chavez MR, Smulian JC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol. 2008;198(5):525 e1-e5.
8. Greene M, Solomon C. Gestational diabetes mellitus-time to treat. N Engl J Med. 2005;352(24):2544-2546.
9. Landon M, Spong C, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339-1348.
10. Bartha J, Martinez-Del-Fresno P, Comino-Delgado R. Early diagnosis of gestational diabetes mellitus and prevention of diabetesrelated complications. Eur J Obstet Gynecol Reprod Biol. 2003; 109(1):41-44.
11. Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes Care. 2007;30(suppl 2): S251-S260.
12. Weinberger SR, Morris TS, Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics. 2000;1(4):395-416.
13. Sundsten T, Eberhardson M, Goransson M, Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci. 2006;4:22.
14. Sundsten T, Ostenson CG, Bergsten P. Serum protein patterns in newly diagnosed type 2 diabetes mellitus-influence of diabetic environment and family history of diabetes. Diabetes Metab Res Rev. 2008;24(2):148-154.
15. Liu X, Feng Q, Chen Y, et al. Proteomics-based identification of differentially-expressed proteins including galectin-1 in the blood plasma of type 2 diabetic patients. J Proteome Res. 2009;8(3): 1255-1262.
16. Riaz S, Alam SS, Akhtar MW. Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal. 2010;51(5):1103-1107.
17. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol. 2001;98(3):525-538.
18. Jensen ON,Mortensen P, Vorm O,MannM. Automation of matrix-assisted laser desorption/ionization mass spectrometry using fuzzy logic feedback control. Anal Chem. 1997;69(9):1706-1714.
19. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S88-S90.
20. Davidsson P, Hulthe J, Fagerberg B, et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res. 2005;46(9): 1999-2006.
21. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75(2):384-390.
22. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolismof human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266(27):18259-18267.
23. Stalenhoef AF, Demacker PN, Lutterman JA, van't Laar A. Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia. Diabetologia. 1982;22(6):489-491.
24. Florez H, Mendez A, Casanova-Romero P, et al. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis. 2006;188(1):134-141.
25. Beliard S, Nogueira JP, Maraninchi M, et al. Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients. Diabet Med. 2009;26(7):736-739.
26. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25(12):1277-1294.
27. Remaley AT, Wong AW, Schumacher UK, Meng MS, Brewer HB Jr, Hoeg JM. O-linked glycosylation modifies the association of apolipoprotein A-II to high density lipoproteins. J Biol Chem. 1993;268(9):6785-6790.
28. Sauvaget D, Chauffeton V, Dugue-Pujol S, et al. In vitro transcriptional induction of the human apolipoprotein A-II gene by glucose. Diabetes. 2004;53(3):672-678.
29. Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr Opin Lipidol. 2004;15(3): 247-253.
30. Roselli della Rovere G, Lapolla A, Sartore G, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13(1):46-51.
31. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, et al. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116(18):2029-2035.
32. Onat A, Hergenc G, Ayhan E, Ugur M, Can G. Impaired anti-inflammatory function of apolipoprotein A-II concentrations predicts metabolic syndrome and diabetes at 4 years follow-up in elderly Turks. Clin Chem Lab Med. 2009;47(11):1389-1394.
33. Park JS, Oh KJ, Norwitz ER, et al. Identification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry. Reprod Sci. 2008;15(5):457-468.
34. Lee J, Park JS, Norwitz ER, et al. Identification and characterization of proteins in amniotic fluid that are differentially expressed before and after antenatal corticosteroid administration. Am J Obstet Gynecol. 2010;202(4):388 e1-388 e10.